| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 170 | 2018 |
| Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation P Armand, HT Kim, J Rhodes, MM Sainvil, C Cutler, VT Ho, J Koreth, ... Biology of Blood and Marrow Transplantation 17 (6), 852-860, 2011 | 143 | 2011 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 116 | 2020 |
| Does iron overload really matter in stem cell transplantation? P Armand, MM Sainvil, HT Kim, J Rhodes, C Cutler, VT Ho, J Koreth, ... American journal of hematology 87 (6), 569-572, 2012 | 101 | 2012 |
| Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... New England Journal of Medicine 389 (1), 33-44, 2023 | 89 | 2023 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 80 | 2019 |
| Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial AR Mato, LE Roeker, JN Allan, JM Pagel, DM Brander, BT Hill, ... American journal of hematology 93 (11), 1394-1401, 2018 | 68 | 2018 |
| Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT P Armand, MM Sainvil, HT Kim, J Rhodes, C Cutler, VT Ho, J Koreth, ... Bone marrow transplantation 48 (1), 146-147, 2013 | 46 | 2013 |
| Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival K Van Besien, P Hari, MJ Zhang, HT Liu, W Stock, L Godley, O Odenike, ... Haematologica 101 (5), 634, 2016 | 44 | 2016 |
| Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma ML Wang, W Jurczak, PL Zinzani, TA Eyre, CY Cheah, CS Ujjani, Y Koh, ... Journal of Clinical Oncology 41 (24), 3988-3997, 2023 | 40 | 2023 |
| Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration DM Stephens, K Boucher, E Kander, SA Parikh, EM Parry, M Shadman, ... Haematologica 106 (11), 2845, 2021 | 33 | 2021 |
| Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen MC Thompson, RA Harrup, CC Coombs, LE Roeker, JJ Pu, MY Choi, ... Blood advances 6 (15), 4553-4557, 2022 | 32 | 2022 |
| A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL AR Mato, LE Roeker, TA Eyre, C Nabhan, N Lamanna, BT Hill, ... Blood advances 3 (10), 1568-1573, 2019 | 31 | 2019 |
| Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1/2 BRUIN study WG Wierda, DJ Lewis, P Ghia, NN Shah, CC Coombs, CY Cheah, ... Blood 140 (Supplement 1), 846-849, 2022 | 29 | 2022 |
| Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes JM Rhodes, VA LoRe III, AR Mato, EA Chong, JC Barrientos, JN Gerson, ... Clinical Lymphoma Myeloma and Leukemia 20 (7), 438-444. e1, 2020 | 28 | 2020 |
| Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia LE Roeker, MS Yazdy, J Rhodes, J Goodfriend, M Narkhede, J Carver, ... JAMA network open 2 (12), e1916326-e1916326, 2019 | 27 | 2019 |
| Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia AR Mato, S Clasen, P Pickens, L Gashonia, J Rhodes, J Svoboda, ... Cancer biology & therapy 19 (1), 1-2, 2018 | 27 | 2018 |
| Reduced-intensity allogeneic transplant for acute myeloid leukemia and myelodysplastic syndrome using combined CD34-selected haploidentical graft and a single umbilical cord … SB Tsai, J Rhodes, H Liu, T Shore, M Bishop, MM Cushing, U Gergis, ... Biology of Blood and Marrow Transplantation 24 (5), 997-1004, 2018 | 26 | 2018 |
| Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 S Montoya, J Bourcier, M Noviski, H Lu, MC Thompson, A Chirino, J Jahn, ... Science 383 (6682), eadi5798, 2024 | 24 | 2024 |
| Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: additional patients and extended follow-up from the phase 1/2 BRUIN study AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... Blood 140 (Supplement 1), 2316-2320, 2022 | 22 | 2022 |
